PatientID: HDR114

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	${f S}$	
	FPV	${f S}$	
	IDV	${f S}$	
	LPV	${f S}$	
	NFV	${f S}$	
	SQV	${f S}$	
	TPV	${f S}$	
NRTI	ABC	LR	
	AZT	IR	
	D4T	IR	
	DDI	IR	D67N;K70R;M184V;T69D
	FTC	$_{ m HR}$	
	LMV	$_{ m HR}$	
	TDF	${f S}$	
NNRTI	DOR	LR	
	EFV	$_{ m HR}$	
	ETR	PLR	P225H;G190A
	NVP	$_{ m HR}$	
	RPV	LR	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
	D67N is a non-polymorphic TAM associated with low-level resistance to AZT.
	K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced
	ABC and TDF susceptibility in combination with other TAMs.
NRTI	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to
	continued treatment with 3TC or FTC because they increase susceptibility to AZT and
	TDF and are associated with clinically significant reductions in HIV-1 replication.
	T69D is a nonpolymorphic mutation selected by early NRTIs that does not appear to
	reduce AZT, ABC, or TDF susceptibility.
NNRTI	G190A is a non-polymorphic mutation that causes high-level resistance to NVP and
	intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV,
	ETR, or DOR.
	P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination
	with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and
	DOR susceptibility.
INSTI	